About Selvita
Selvita has two primary focus areas:
– to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services and
– as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.
More
Drug Discovery Services
Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.
We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.
More
Research and Development
In its internal research and development efforts, Selvita focuses on different dimensions of oncology.
The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, in acute myeloid leukemia.
